Vistagen Therapeutics Business Summary

Vistagen Therapeutics, Inc. (VTGN) is a clinical-stage biopharmaceutical company that generates revenue primarily through sublicensing agreements and non-product revenue, as it currently lacks FDA-approved products for commercial sale. The company operates within the neuroscience segment, specializing in the development of "pherines"—a novel class of rapid-onset, intranasal neuroactive steroids designed to treat psychiatric and neurological disorders without systemic absorption. Its primary business focus is the clinical advancement of its lead candidates: fasedienol (PH94B) for social anxiety disorder, itruvone (PH10) for major depressive disorder, and refisolone (PH80) for menopausal vasomotor symptoms. Vistagen competes directly with other neuroscience-focused firms such as Axsome Therapeutics, Relmada Therapeutics, Intracellular Therapies, and ACADIA Pharmaceuticals, positioning itself as a pioneer in non-systemic, nose-to-brain neurocircuitry modulation. The company was founded in 1998 by Dr. Ralph Snodgrass and Dr. Gordon Keller, pioneers in stem cell systems for drug discovery. The current leadership team is headed by President and CEO Shawn K. Singh, J.D., who has led the company since 2009 and brings over 30 years of experience from roles at Artemis Neuroscience and Cato BioVentures. Key executives include CFO Nick B. Tressler, COO Joshua S. Prince, and Chief Corporate Development Officer Elissa Cote, supported by Board Chair Maggie FitzPatrick. Vistagen’s strategic direction is further guided by a board that includes veterans like Jon S. Saxe and is backed by notable institutional investors such as OrbiMed Advisors, TCG Crossover Management, and Vanguard Group.